Technology
Health
Biotechnology

Audentes Therapeutics

$36.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.64 (-6.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BOLD and other stocks, options, ETFs, and crypto commission-free!

About

Audentes Therapeutics, Inc. Common Stock, also called Audentes Therapeutics, is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Read More Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Employees
207
Headquarters
San Francisco, California
Founded
2012
Market Cap
1.72B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
478.98K
High Today
$38.90
Low Today
$36.61
Open Price
$38.83
Volume
283.68K
52 Week High
$46.18
52 Week Low
$17.95

Collections

Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America

News

MarketBeatMar 14

Stock Price, News, & Analysis for Audentes Therapeutics

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in prec...

1
PR NewswireMar 8

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on March 7, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to six in...

49
Yahoo FinanceMar 7

Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know

As of late, it has definitely been a great time to be an investor in Rent-A-Center. Audentes Therapeutics (BOLD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side a...

28

Earnings

-$0.97
-$0.89
-$0.82
-$0.74
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.